RxDoctor Payments Data

Hooman Harooni, MD

Ophthalmology · Toledo, OHNPI 1609097369

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 58 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$246
  • Alcon$237
  • Tarsus Pharmaceuticals, Inc.$202
  • Bausch & Lomb Americas Inc.$114
  • Shire North American Group Inc$63
  • Novartis$56
  • plus $342 from 11 others

What the payments were for

  • Food & beverage$1,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260 in reported general payments places this provider in the 50th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$452,017
Medicare patients
1,051
Services billed
2,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$80,500
XiidraLifitegrast32$48,718
Cyclosporine51$34,508
Prednisolone Acetate630$22,860
TobradexTobramycin/Dexamethasone24$20,216
Tobramycin-DexamethasoneTobramycin/Dexamethasone322$12,856
Fluorometholone113$9,001
TyrvayaVarenicline Tartrate13$8,104
CombiganBrimonidine Tartrate/Timolol19$6,623
LumiganBimatoprost11$5,839
Latanoprost362$4,180
MoxifloxacinMoxifloxacin Hcl120$3,382
Acyclovir129$3,069
Brimonidine Tartrate119$2,866
Timolol Maleate167$2,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$246$92,961107 claims
Bausch & Lomb Americas Inc.Xiidra$114$48,71832 claims
Oyster Point Pharma, Inc.Tyrvaya$16$8,10413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →